

International Symposium on Trends in Radiopharmaceuticals (ISTR-2019)
28 October–1 November 2019, Vienna, Austria

| | Monday 28-10-2019 | Tuesday 29-10-2019 | Wednesday 30-10-2019 | Thursday 31-10-2019 | Friday 1-11-2019 | |
|-------------|--|---|---|---|--|---|
| 09:00–10:30 | Registration (8:00–9:30) | S.4 Production of radiopharmaceuticals: Theranostic | S.7 Production of radiopharmaceuticals: PET | Clinical advances in nuclear medicine | S.11 Production of alpha emitters and radiopharmaceuticals | |
| | Opening Session (9:30–10:30) | 09:00 J. Lewis: Development and application of monoclonal antibody based radiopharmaceuticals | 09:00 P. Bisiga: Recent advances in the development of ¹⁸ F and ¹¹ C radiopharmaceuticals | 09:00 D. Paez: IAEA activities related to nuclear medicine | 09:00 A. Morgenstern: Production and quality control of radiopharmaceuticals labelled with Actinium-225 and Bismuth-213 | 09:00 D. Yang: Opening Remarks by Deputy Director General, Head of the Department of Technical Cooperation |
| | | 09:25 C. Decristoforo: Theranostic radiopharmacy | 09:25 C. Decristoforo: Recent advances in the development of ⁶⁸ Ga radiopharmaceuticals | 09:30 H. Macapinlac: Recent advances in nuclear medicine: Diagnostic and therapy | 09:30 C. Cutler: U.S. DOE Trilab production effort to provide accelerator produced ²²⁵ Ac | 09:10 S. Abdulrazzak: Technical cooperation programme: enhancing capacities in radiopharmacy in Africa |
| | | 09:45 V. Gadefthin: Innovative medical radioisotopes for theranostic application, and how they are produced | 09:45 I. Aljazzar: Synthesis and in vitro and in vivo evaluation of ¹²⁵ I labelled PSMA peptides: Potential theranostic radiopharmaceuticals for prostate cancer | 10:00 D. Le: Production and use of cyclotron-produced radiopharmaceuticals at MD Anderson Cancer Center | 10:00 M. Lesinski: Recent results of the joint CNL and TRIUMF project on the production of Ac-225 | 09:30 R. Leyva Montaña: Sustainable production of ²²³ Rn generators and radiopharmaceuticals on IAEA/Cuban experience |
| | | 10:00 B. Alizadeh: Preparation and preclinical evaluation of ⁶⁴ Cu NOTA-zarit (MUC1) as a radioimmunoconjugate for diagnosis of MUC1+ breast cancer by PET | 10:00 V. Kumar: A radiocopper somatostatin analog (Cu-Sarfatel) for NET theranostics | 10:15 W. Chintawan: Comparative study of [¹⁸ F]PSMA-1007 and [⁶⁸ Ga]PSMA-11 for prostate cancer PET imaging in Thailand | 10:15 O. Paez: Argentinian project for developing production of ²²⁵ Ac and ²¹¹ Bi in cyclotrons for targeted therapy | 10:00 Y. Chakrova: Gel generator production project in Kazakhstan: IAEA support |
| | | 10:15 L. Melendez-Alafort: Development of a new prostate cancer theranostic radiopharmaceutical | | | | 10:15 A. Duran: Strengthening capacities for the development of radiotracers labelled with ¹⁸ F, different from fluorodeoxyglucose in the FCDN |
| 10:30-11:00 | Morning Coffee Break | | | | | |
| 11:00-12:30 | S.1 Production of medical radioisotopes: Research Reactor | S.5 Production of radiopharmaceuticals: SPECT | S.8 QA/QC/Pre-clinical | S.12 Emerging radioisotopes for radiopharmacy | WNU OLYMPIAD: FINALS | |
| | 11:00 M. Venkatesh: Production of reactor based radioisotopes: An international scenario | 11:00 A. Duatti: Revisiting ^{99m} Tc radiopharmaceuticals with recent advances in chemistry & imaging tools | 11:00 S. Rubow: Quality control of hospital based radiopharmaceuticals | 11:00 V. Radchenko: Development of production strategies for new emerging research radionuclides using cyclotrons | | |
| | 11:25 R. Mikolajczak: Production and supply of medical radioisotopes: A Polish experience | 11:25 G. Ferro-Flores: Production of radiolabelled peptides for SPECT-based theranostics | 11:20 J. Smith: Development and preclinical evaluation of ¹⁴ C radiolabelled compounds | 11:25 M. Ávila Rodríguez: Emerging clinical applications of [⁶⁴ Cu]CuCl ₂ radiopharmaceutical | | |
| | 11:45 J.L. Crudo: Laboratory scale production of medium specific activity ¹⁷⁷ Lu (carrier added) through the ¹⁷⁶ Lu (n,γ) ¹⁷⁷ Lu nuclear reaction under standardized conditions | 11:45 S. Bouyoucef: Radiopharmacy and growth of nuclear medicine in developing countries | 11:40 B. Guérin: Preclinical evaluation of ⁶⁸ Ga-PET tracers using ⁶⁸ Ga produced by cyclotron, a Canadian experience | 11:45 P. Martini: Towards large-scale ⁶⁸ Ga cyclotron production | | |
| | 12:00 B. Ocampo-García: Synthesis and neutron activation of Lu ₂ O ₃ nanoparticles functionalized with target specific peptides | 12:00 C. Balzati: Selective αvβ3 integrin detection using [¹¹¹ In]NPNP437-tagged RGDcyclic peptides: synthesis and pharmacological studies | 12:00 E. Bombardieri: Ethics in animal experiments in nuclear medicine and the application of the directive 2010/63 EU | 12:00 I. Cieszykowska: Production of ⁴⁵ Sc from ⁴⁴ Ca comparison of four separation methods | | |
| | 12:15 T. Tielens: Towards a robust supply chain for medical radioisotopes | 12:15 E. Araújo Perini: The past, present and future trends in radiopharmaceuticals production in Brazil | 12:15 R. Teodoro: PET for the imaging of cerebral α7 acetylcholine receptors: from tracer development to clinical application | 12:15 G. Pupillo: Accelerator-based production of ⁴⁵ Sc: Results of the PASTA project | | |
| 12:30-14:00 | Working Lunch: MITabs (12:45 - 13:45) | | Lunch Break (12:30-14:00) | | | |
| 14:00-15:30 | S.2 Production of medical radioisotopes: Accelerators | Poster Session I | S.9 Health regulations: Production of radiopharmaceuticals | Poster Session II | Closing Session / Awards Ceremony | |
| | 14:00 S.M. Qaim: Accelerator based production of non-radionuclides | | 14:00 S. Kopp: A move towards harmonization of GMP regulations in radiopharmacy | | | |
| | 14:25 S. Lopi: Production of radiometals using a 24 MeV cyclotron | | 14:20 C. Decristoforo: The status of radiopharmaceutical regulations in Europe | | | |
| | 14:45 A. Abrunhosa: Production of radiometals using liquid targets: status and perspectives | | 14:40 S. Lyashchenko: The status of radiopharmaceutical regulations in the US | | | |
| | 15:00 J. Hoan Park: Radiosotope production and development with 30MeV cyclotron | | 15:00 Y. Chakrova: GMP certification of radiopharmaceutical production facility in Kazakhstan | | | |
| | 15:15 V. Radchenko: Production and application of ²²⁵ Ac/ ²¹¹ Bi: TRIUMF experience and perspectives | | 15:15 S. Nazarenko: Compounding radiopharmaceuticals: any regulatory difference with extemporaneous preparation? | | | |
| 15:30-16:00 | Coffee Break | | | | | |
| 16:00-17:30 | S.3 Production of medical radioisotopes: Generators | S.6 Production of radiopharmaceuticals: Therapy | S.10 New trends in radiopharmaceuticals: Chemistry | S.13 Radiopharmacy installations | | |
| | 16:00 J. Osso Junior: Role of the IAEA on the supply of ⁹⁹ Mo | 16:00 M.R.A. Pillai: Production and quality control of bone pain palliation agents using β-emitters | 16:00 B. Guérin: Development and evaluation of chelators for specific radiometals | 16:00 A. Duatti: How to set up a medium size ^{99m} Tc generator facility: IAEA experience | | |
| | 16:15 B. Grimshaw: Safeguards on the production of medical radioisotopes | 16:25 J. R. Zeveaort: Comparison of promising new short range therapeutic radiopharmaceuticals using ²²⁵ Ac, ²¹³ Bi and ¹⁴¹ Ba | 16:20 S. Lyashchenko: Novel radiopharmaceuticals for clinical translation | 16:25 V. Kumar: Design and successful operation of a SPECT hospital radiopharmacy | | |
| | 16:30 C. Cutler: Supply of ⁹⁹ Mo: Focus on US | 16:45 V. Chitayil: Freeze-dried kit for quick and efficient preparation of ¹⁸⁸ Re-DED/βiodol in hospital radiopharmacy | 16:40 J. Smith: Translation of new chelators for old pairs: Tc/Re NODAGA, etc | 16:45 M.R.A. Pillai: Cyclotron and PET radiopharmacy installation: experience in setting up in a commercial centre | | |
| | 16:55 B. Zhukov: Radionuclide production at high energy accelerators: the new possibilities for radioisotope generators | 17:00 C. H. Yeong: Production of Theranostic ¹⁸⁸ Samarium-labelled Polystyrene Microspheres for Hepatic Radioembolization | 17:00 K. Katti: Radioactive Gold ¹⁹⁸ Au nanoparticles in nanomedicine | 17:00 U. Bhonsle: How to set up a PET radiopharmaceutical facility: IAEA experiences | | |
| | 17:15 R. Walczak: Cyclotron production of ⁴⁷ Ca for ⁴⁷ Ca/ ⁴⁷ Sc generator | 17:15 A. Chakraborty: Radiolabeling and pre-clinical evaluation of Y-90-DOTA-TATE - formulated using Y-90-acetate from high level liquid waste | 17:15 P. Brust: New strategies for imaging of brain cancer with radiopharmaceuticals | 17:15 K. Washiyama: An effort to diagnostic and therapeutic nuclear medicine at the Fukushima Medical University using two medical cyclotrons | | |
| 18:00-20:00 | Welcome reception (18:00–20:00) MOE | | India: Side event | | | |
| | Board Room B/M1 | Boardroom M2 | Women in Radiopharmaceutical Sciences: Challenges and opportunities | | S.14 IAEA Databases and Apps (17:30-18:30) | |